重组人血管内皮抑制素注射液联合洛铂对恶性胸腔积液患者生活质量及免疫功能的影响

目的:探讨重组人血管内皮抑制素注射液联合洛铂对恶性胸腔积液患者生活质量及免疫功能的影响。方法:选择2015年3月至2017年3月期间我院收治的恶性胸腔积液患者56例为研究对象,按照不同的治疗方式分为研究组(n=28)和对照组(n=28)。对照组给予洛铂治疗,研究组给予重组人血管内皮抑制素注射液联合洛铂治疗。比较两组患者治疗前后生活质量变化、免疫功能变化、临床疗效和不良反应发生情况。结果:研究组患者生活质量改善率高于对照组(P0.05)。治疗前,两组免疫功能指标含量经统计分析差异无统计学意义(P0.05),与治疗前比较,两组治疗后4周CD3~+、CD4~+、CD4~+/CD8~+、NK含量均升高,CD8+含量降低,且研究组CD3~+、CD4~+、CD4~+/CD8~+、NK含量较对照组升高,CD8~+含量较对照组降低(P0.05)。研究组总有效率为78.57%,与对照组的46.43%比较差异有统计学意义(P0.05)。两组患者心脏反应、呕吐、恶心、血小板减少、白细胞减少、贫血、乏力发生率比较差异均无统计学意义(P0.05)。结论:重组人血管内皮抑制素注射液联合洛铂治疗恶性胸腔积液具有较好的疗效,其可以改善患者生活质量,提高免疫功能,且不会增加患者不良反应,值得临床推广。

Effect of Recombinant Human Endostatin Injection Combined with Lobaplatin on Quality of Life and Immune Function in Patients with Malignant Pleural Effusion

ABSTRACT Objective: To investigate the effect of Recombinant Human Endostatin Injection combined with lobaplatin on the quality of life and immune function in patients with malignant pleural effusion. Methods: A total of 56 patients with malignant pleural effusion, who were treated in the socond People''s Hospital in Jingmen from March 2015 to March 2017, were selected and divided into study group (n=28) and control group (n=28) according to the different treatment methods. The control group was given chemotherapy with lobaplatin, and the study group was treated with Recombinant Human Endostatin Injection combined with lobaplatin. The changes of the quality of life, the changes of immune function before and after treatment, the clinical effect and the occurrence of adverse reactions were compared between the two groups. Results: Improvement rate of quality of life of the patients in the study group was higher than that of the control group (P<0.05). Before treatment, there was no significant difference in the contents of immune function indexes between the two groups by statistical analysis(P>0.05). Compared with those before treatment, the contents of CD3⁺, CD4⁺, CD4⁺/CD8⁺ and NK in the two groups 4 weeks after treatment were increased, while the content of CD8⁺ was decreased, the contents of CD3⁺, CD4⁺, CD4⁺/CD8⁺ and NK in the study group were higher than those in the control group, and the content of CD8⁺ in the study group was lower than that in the control group (P<0.05). The total effective rate of the study group was 78.57%, compared with the 46.43% of the control group, the difference was statistically significant (P<0.05). There was no significant difference in the incidence of cardiac reactions, vomiting, nausea,thrombocytopenia, aleucocytosis, anemia and fatigue between the two groups (P>0.05). Conclusion: Recombinant Human Endostatin Injection combined with lobaplatin has a good effect in the treatment of malignant pleural effusion. It can improve the quality of life of the patients, improve the immune function, and it will not increase the adverse reaction of the patients,which is worthy of clinical promotion.